The Transthyretin (TTR) amyloidosis market is expected to register a sturdy growth during the forecast period. Transthyretin (TTR) amyloidosis is a medical condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in a body's organs and tissues. It generally affects peripheral neuropathic or autonomic neuropathy system and cardiac system. The cardiac form of Transthyretin (TTR) amyloidosis puts patients at the risk of arrhythmia, cardiomegaly, and orthostatic hypertension. The global ATTR market is likely to exhibit a robust growth during the forecast period due to the probability of rising number of ATTR therapeutic drugs launches, increasing African-American population as they are genetically susceptible to amyloidosis, increasing healthcare awareness among people, and rising average income of individuals. However, the growth of this market can be hindered by stringent regulatory policies, the high cost of ATTR drugs, incorrect diagnosis of ATTR disorders and limitations of clinical trials. Lack of knowledge about this condition and unavailability of advanced diagnostic methods in the middle-income countries are the major challenges to the market.
Market Players
- Alnylam Pharmaceuticals
- Pfizer
- Merck
- Ionis Pharmaceuticals Inc.
- Corino Therapeutics Inc
- Arcturus Therapeutics
- Proclara Bioscience
Market Segmentation
The global Transthyretin (TTR) amyloidosis market is segmented on the basis of disease type, treatment, gender, and end-user. Considering the type of disease, the market is segmented into Transthyretin (TTR) familial amyloid polyneuropathy, Transthyretin (TTR) familial amyloid cardiomyopathy, and others. On the basis of treatment, the market is segmented into small molecules treatment, RNAi therapy, organ transplantation, and others. Small molecules treatment is further segmented into tafamidis and diflunisal. On gender basis, it is segmented into male and female. According to end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, and others.
Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.
Market Segmentation
Global Transthyretin (TTR) Amyloidosis Market, by Disease Type
- Transthyretin (TTR) Familial Amyloid Polyneuropathy
- Transthyretin (TTR) Familial Amyloid Cardiomyopathy
- Others
Global Transthyretin (TTR) Amyloidosis, by Treatment
- Small molecules treatment
- RNAi therapy
- Organ Transplantation
Global Transthyretin (TTR) Amyloidosis Market, by Gender
Global Transthyretin (TTR) Amyloidosis Market, by End-User
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Others
Request Customization
Get a Sample
Get a Sample
Request Customization